Persistent Lyme Empiric Antibiotic Study Europe
Persistent Lyme Empiric Antibiotic Study Europe. A Prospective, Randomised Study Comparing Two Prolonged Oral Antibiotic Strategies After Initial Intravenous Ceftriaxone Therapy for Patients With Symptoms of Proven or Possible Persistent Lyme Disease
Sponsor: Radboud University Medical Center
Listed as NCT01207739, this PHASE4 trial focuses on Borrelia Infection and Lyme Disease and remains completed. Sponsored by Radboud University Medical Center, it has been updated 7 times since 2010, reflecting limited change activity. This study is part of the global effort to build evidence for infectious disease interventions.
Change History
7 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE4
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE4
-
Mar 2022 — Jul 2024 [monthly]
Completed PHASE4
-
Jan 2021 — Mar 2022 [monthly]
Completed PHASE4
-
Jun 2018 — Jan 2021 [monthly]
Completed PHASE4
▶ Show 2 earlier versions
-
Feb 2017 — Jun 2018 [monthly]
Completed PHASE4
-
Jan 2017 — Feb 2017 [monthly]
Completed PHASE4
First recorded
Sep 2010
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Radboud University Medical Center
- Sint Maartenskliniek
- ZonMw: The Netherlands Organisation for Health Research and Development
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
- • Nijmegen, Netherlands